BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25456645)

  • 1. Oral antihyperglycemic treatment options for type 2 diabetes mellitus.
    Brietzke SA
    Med Clin North Am; 2015 Jan; 99(1):87-106. PubMed ID: 25456645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J
    Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral hypoglycemic agents on platelet function.
    Papazafiropoulou A; Papanas N; Pappas S; Maltezos E; Mikhailidis DP
    J Diabetes Complications; 2015 Aug; 29(6):846-51. PubMed ID: 26026848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients.
    Susilawati E; Levita J; Susilawati Y; Sumiwi SA
    Med Sci (Basel); 2023 Aug; 11(3):. PubMed ID: 37606429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
    Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    McGill JB
    J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL; Zhang W; McCollum M
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating oral anti diabetic drug: alternatives to metformin.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Apr; 65(4):440-1. PubMed ID: 25976586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
    Kokić S; Buković D; Radman M; Capkun V; Gabrić N; Lesko V; Karelović D; Stancerić T
    Coll Antropol; 2003 Jun; 27(1):181-7. PubMed ID: 12974145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.